Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; St. George's Hospital Medical School, University of London, London, United Kingdom; Arrow project for medical research education, Sheba Medical Center, Ramat-Gan, Israel.
Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Neurobiol Dis. 2023 Jan;176:105953. doi: 10.1016/j.nbd.2022.105953. Epub 2022 Dec 6.
Pediatric onset multiple sclerosis patients (POMS) are defined as multiple sclerosis with an onset before the age of 18 years. Compared to adult onset multiple sclerosis (AOMS), POMS has more severe disease activity at onset, but better recovery. Little is known about the molecular mechanism responsible for the differences in the clinical presentations.
Peripheral Blood Mononuclear Cells samples were taken from 22 POMS patients (mean age 14.1 ± 2.4 years, 15 females, 7 male), and 16 AOMS patients, (mean age 30.8 ± 6.1 years,10 females, 6 males), and gene-expression were analyzed using Affymetrix Inc. HU-133-A2 microarrays. Differentially Expressed Genes (DEGs) that significantly distinguished between POMS and AOMS with pvalue <0.05 after false discovery rate correction were evaluated using Partek software. Twenty-one matched age and gender control was applied to clarify age-related changes. Clinical assessment was performed by analysis of expanded disability status scale (EDSS) and brain MRI lesion loads. Gene functional analysis was performed by Ingenuity Pathway Analysis software.
Compared to AOMS, POMS had higher EDSS (3.0 IQR 2.0-3.0 and 2.0 IQR 2.0-3.0, p = 0.005), volume of T1 (2.72 mm, IQR 0.44-8.39 mm and 0.5 mm IQR 0-1.29 mm respectively, p = 0.04) and T2 (3.70 mm, IQR 1.3-9.6 and 0.96 mm, IQR 0.24-4.63 respectively, p = 0.02) brain MRI lesions. The POMS transcriptional profile was characterized by 551 DEGs, enriched by cell cycling, B lymphocyte signaling and senescent pathways (p < 0.02). Of these, 183 DEGs significantly correlated with T2 lesions volume. The POMS MRI correlated DEGs (n = 183) and their upstream regulators (n = 718) has overlapped with age related DEGs obtained from healthy subjects (n = 497). This evaluated common DEGs (n = 29) defined as POMS age-related regulators, suggesting to promote effect on disease severity.
Our finding of higher transcriptional levels of genes involved in cell cycle, cell migration and B cell proliferation that promoted by transcriptional level of age-associated genes and transcription factors allows better understanding of the more aggressive clinical course that defines the POMS.
儿科发病多发性硬化症(POMS)患者被定义为发病年龄在 18 岁以下的多发性硬化症患者。与成人发病多发性硬化症(AOMS)相比,POMS 在发病时疾病活动更为严重,但恢复情况较好。对于导致临床表现差异的分子机制知之甚少。
从 22 名 POMS 患者(平均年龄 14.1 ± 2.4 岁,15 名女性,7 名男性)和 16 名 AOMS 患者(平均年龄 30.8 ± 6.1 岁,10 名女性,6 名男性)中采集外周血单核细胞样本,并使用 Affymetrix Inc. HU-133-A2 微阵列进行基因表达分析。使用 Partek 软件评估差异表达基因(DEGs),这些基因在经过错误发现率校正后,通过 p 值 <0.05 显著区分 POMS 和 AOMS。应用 21 个匹配年龄和性别的对照来明确与年龄相关的变化。通过分析扩展残疾状况量表(EDSS)和脑 MRI 病变负荷来进行临床评估。通过 Ingenuity Pathway Analysis 软件进行基因功能分析。
与 AOMS 相比,POMS 的 EDSS 更高(3.0 IQR 2.0-3.0 和 2.0 IQR 2.0-3.0,p = 0.005),T1 体积更大(2.72 mm,IQR 0.44-8.39 mm 和 0.5 mm,IQR 0-1.29 mm,p = 0.04)和 T2(3.70 mm,IQR 1.3-9.6 和 0.96 mm,IQR 0.24-4.63,p = 0.02)脑 MRI 病变。POMS 的转录谱特征是 551 个差异表达基因,富含细胞周期、B 淋巴细胞信号和衰老途径(p < 0.02)。其中,183 个差异表达基因与 T2 病变体积显著相关。POMS MRI 相关 DEGs(n = 183)及其上游调节剂(n = 718)与从健康受试者中获得的与年龄相关的 DEGs(n = 497)重叠。这评估了 29 个共同的 DEGs(n = 29),定义为 POMS 年龄相关调节剂,表明它们对疾病严重程度有促进作用。
我们发现与细胞周期、细胞迁移和 B 细胞增殖相关的基因转录水平较高,这些基因受到与年龄相关的基因和转录因子的转录水平的促进,这有助于更好地理解定义 POMS 的更具侵袭性的临床病程。